On March 21, 2017 the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client Biogen, upholding a patent covering the multiple sclerosis drug Tecfidera in an inter partes review requested by the Coalition for Affordable Drugs. This was the Coalition's second failed attempt to invalidate the patent-in-suit. According to the decision, Biogen's experts presented sufficient evidence to demonstrate that a combination of previous patents, a clinical trial, and other prior art would not have made it obvious for an artisan to choose the 480 milligrams per day dosage cited in the patent.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.